Results 91 to 100 of about 5,574 (244)

Sovereign Immunity for Rent: How the Commodification of Tribal Sovereign Immunity Reflects the Failures of the U.S. Patent System [PDF]

, 2019
Last year, a Fortune 500 pharmaceutical company attempted to rent the sovereign immunity of an American Indian tribe in order to shield its patents on a dry-eye drug from invalidation by generic competitors in inter partes review.
Geddes, Katrina G
core   +1 more source

Addressing challenges for sustainable healthcare in Central and Eastern Europe [PDF]

, 2016
All European countries face increasing challenges in the provision of equitable and comprehensive healthcare for their citizens in view of a number of factors including changing demographics and the launch of new premium priced medicines.
Godman, Brian, Haycox, Alan, Martin, Antony Paul, Novakovic, Tanja, Ootwijn, Wija, Parker, Mark, Tesic, Danka   +6 more
core   +3 more sources

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, Volume 159, Issue 1, Page 159-172, 1 July 2026.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

Arthritis Research & Therapy
Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O).
Marina G. Birck, Jessica Boivin, Laura Yan, Nathalie Carrier, Cristiano S. Moura, Walter P. Maksymowych, Gilles Boire, Denis Choquette, Luck Lukusa, Michael Mallinson, Linda Wilhelm, Autumn Neville, Sasha Bernatsky   +12 more
doaj   +1 more source

From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry [PDF]

Technological Forecasting and Social Change, 2019
Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology ...
openaire   +1 more source

Mecapegfilgrastim for Prophylaxis of Immunochemotherapy‐Induced Neutropenia in Patients With Diffuse Large B‐Cell Lymphoma: A Multicenter Pilot Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy‐induced neutropenia in treatment‐naive patients with diffuse large B‐cell lymphoma (DLBCL). Methods In this open‐label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no ...
Jie Wang, He Li, Qiaochu Lin, Yong Guo, Hongbing Ma, Bing Xiang, Chenlu Yang, Kai Shen, Chunlan Zhang, Kun Yang, Chunrong Ma, Hong Zhai, Jin Wei, Yan Zuo, Jie Zhou, Ting Niu   +15 more
wiley   +1 more source

An overall comparison of small molecules and large biologics in ADME testing [PDF]

, 2016
Biologics mainly monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) as new therapeutics are becoming increasingly important biotherapeutics.
Hong Wan
core   +3 more sources